AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30653147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-administration of remifentanil (Group R)
Number of subjects: 60
Study 29891003 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture on the acu-point Bi'nao
Number of subjects: 0
Study 29891003 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture on the sham Bi'nao
Number of subjects: 0
Study 29891003 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional acupuncture therapy
Number of subjects: 0
Study 26706403 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time unconditional income transfers to all households (T1)
Number of subjects: 0
Study 26706403 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time unconditional income transfers to the poorest 20% of households (T2)
Number of subjects: 0
Study 26706403 — intervention group
Group type: COMPARATOR
Intervention: Control group (other villages)
Number of subjects: 0
Study 24659430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal OXT (24 IU)
Number of subjects: 60
Study 24659430 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study 22669143 — intervention group
Group type: EXPERIMENTAL
Intervention: Catuama (herbal compound), 2 capsules each day for 8 weeks
Number of subjects: 72
Study 22669143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 72
Study 21130328 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel orthodontic wires exposed in vivo for varying durations
Number of subjects: 30
Study 21130328 — intervention group
Group type: COMPARATOR
Intervention: As-received control samples of stainless steel orthodontic wires
Number of subjects: 30
Study 17414236 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (n = 18)
Number of subjects: 39
Study 17414236 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 39
Study 10642289 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 39
Study 10642289 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP (administered at ineffective pressure)
Number of subjects: 39
Study 9071515 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel rod (LNG ROD) implants
Number of subjects: 1198
Study 9071515 — intervention group
Group type: COMPARATOR
Intervention: NORPLANT implants
Number of subjects: 1198
Study 8446137 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 to 50 mg twice daily, with or without hydrochlorothiazide)
Number of subjects: 379
Study 8446137 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 20 mg per day, with or without hydrochlorothiazide)
Number of subjects: 379
Study 8446137 — intervention group
Group type: COMPARATOR
Intervention: Captopril and Enalapril
Number of subjects: 379
Study 3941567 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary artery grafts
Number of subjects: 98
Study 3941567 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein grafts with placebo
Number of subjects: 98
Study 3941567 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein grafts with aspirin and dipyridamole
Number of subjects: 98
Study 3941567 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein grafts
Number of subjects: 98
Study 29488276 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide, 5 μg BID for 30 days
Number of subjects: 0
Study 29488276 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide, 3 mg daily for 5 weeks
Number of subjects: 0
Study 29488276 — intervention group
Group type: COMPARATOR
Intervention: GG genotype (control group)
Number of subjects: 0
Study 27198235 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent incentives (CS)
Number of subjects: 41
Study 27198235 — intervention group
Group type: COMPARATOR
Intervention: Non-contingent incentives (NS)
Number of subjects: 41
Study 25141246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/famotidine fixed-dose tablet
Number of subjects: 776
Study 25141246 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 776
Study 23394465 — intervention group
Group type: EXPERIMENTAL
Intervention: Web application
Number of subjects: 34
Study 23394465 — intervention group
Group type: EXPERIMENTAL
Intervention: Video conferencing (Skype)
Number of subjects: 34
Study 23394465 — intervention group
Group type: COMPARATOR
Intervention: Standard home health care (Control)
Number of subjects: 34
Study 20501682 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 replacement therapy
Number of subjects: 94
Study 17594774 — intervention group
Group type: EXPERIMENTAL
Intervention: Case vignette describing a man with current symptoms of mania
Number of subjects: 387
Study 17594774 — intervention group
Group type: EXPERIMENTAL
Intervention: Case vignette describing a man with current symptoms of depression
Number of subjects: 387
Study 17594774 — intervention group
Group type: COMPARATOR
Intervention: General public attitudes
Number of subjects: 387
Study 16669971 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 60
Study 16669971 — intervention group
Group type: COMPARATOR
Intervention: fosinopril
Number of subjects: 60
Study 12785122 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of 500 mg acetylsalicylic acid (ASA) and 30 mg pseudoephedrine (PSE)
Number of subjects: 12
Study 12785122 — intervention group
Group type: COMPARATOR
Intervention: Equally single dosed drugs (ASA and PSE)
Number of subjects: 12
Study 10744291 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suturing
Number of subjects: 101
Study 10744291 — intervention group
Group type: COMPARATOR
Intervention: Interrupted suturing
Number of subjects: 101
Study 8862260 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIFN-gamma with thalidomide and conventional multidrug chemotherapy
Number of subjects: 0
Study 8862260 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIFN-gamma only
Number of subjects: 0
Study 8862260 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIFN-gamma without concomitant chemotherapy
Number of subjects: 0
Study 1299501 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO, 7% carbohydrate)
Number of subjects: 10
Study 29458323 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane adhesive keyhole dressing together with a polyurethane semipermeable transparent dressing
Number of subjects: 300
Study 29458323 — intervention group
Group type: COMPARATOR
Intervention: Usual care (polyurethane adhesive keyhole dressing)
Number of subjects: 300
Study 29458323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedated patients
Number of subjects: 300
Study 27106721 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+EPA treatment (4 g/day for 15-18 months)
Number of subjects: 90
Study 27106721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25518878 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive motivational telephone outreach with eight weeks of nicotine replacement therapy and eight sessions of specialized telephone counseling over two months, followed by monthly maintenance counseling for four months.
Number of subjects: 3840
Study 25518878 — intervention group
Group type: COMPARATOR
Intervention: VHA usual care (control group).
Number of subjects: 3840
Study 22456094 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 22456094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20153158 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (4 microg, inhaled 6-9 times daily, with a night pause; dose reduced to 2 microg if side effects occurred)
Number of subjects: 63
Study 18418961 — intervention group
Group type: EXPERIMENTAL
Intervention: Removing dampness and purgative (RDP) method plus routine Western medicine
Number of subjects: 120
Study 18418961 — intervention group
Group type: COMPARATOR
Intervention: Routine Western medicine
Number of subjects: 120
Study 16827811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol plus 5-ISMN
Number of subjects: 109
Study 16827811 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic band ligation
Number of subjects: 109
Study 12806495 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Unit (SU)
Number of subjects: 74
Study 12806495 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ward (GW)
Number of subjects: 74
Study 10812982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanov
Number of subjects: 50
Study 10812982 — intervention group
Group type: COMPARATOR
Intervention: Analgin
Number of subjects: 50
Study 8841801 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary trypsin inhibitor (UTI), vaginal suppository (5000 U) daily for 2 weeks
Number of subjects: 0
Study 8841801 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine, high doses up to 300 micrograms/min initially, then maintenance dose until 35 weeks of gestation
Number of subjects: 0
Study 1310715 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 400 mg once daily for 3 days
Number of subjects: 404
Study 1310715 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg twice daily for 7 days
Number of subjects: 404
Study 6596055 — intervention group
Group type: EXPERIMENTAL
Intervention: High P/S ratio diet
Number of subjects: 0
Study 6596055 — intervention group
Group type: COMPARATOR
Intervention: Low P/S ratio diet (Control)
Number of subjects: 0
Study 30576841 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training (VR-JIT)
Number of subjects: 0
Study 30576841 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS services-as-usual + VR-JIT
Number of subjects: 0
Study 30576841 — intervention group
Group type: COMPARATOR
Intervention: IPS services-as-usual
Number of subjects: 0
Study 30070579 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect measures of implicit attitudes
Number of subjects: 24015
Study 30070579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-attitude model
Number of subjects: 24015
Study 30070579 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of indirect measures
Number of subjects: 24015
Study 27052635 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) for 52 weeks
Number of subjects: 87
Study 27052635 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET) for 52 weeks
Number of subjects: 87
Study 27052635 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET) for 24 weeks (open-label phase)
Number of subjects: 87
Study 25116690 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (Narrative Exposure Therapy)
Number of subjects: 34
Study 25116690 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 34
Study 25116690 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD individuals
Number of subjects: 34
Study 25116690 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 34
Study 22239483 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐up (ABC) intervention
Number of subjects: 120
Study 22239483 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 120
Study 20016870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin plus amoxicillin‐clavulanate (Group A)
Number of subjects: 58
Study 20016870 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (Group B)
Number of subjects: 58
Study 18585831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine (PV) + Influenza vaccine (IV)
Number of subjects: 167
Study 18585831 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine (IV)
Number of subjects: 167
Study 15606590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamin 18 infusion (500 mls) administered immediately after induction of anaesthesia
Number of subjects: 20
Study 15606590 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Vamin 18 administered)
Number of subjects: 20
Study 12113994 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP care
Number of subjects: 20
Study 12113994 — intervention group
Group type: COMPARATOR
Intervention: Control care
Number of subjects: 20
Study 10434232 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate vaginal ovule
Number of subjects: 12
Study 10434232 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin phosphate vaginal cream
Number of subjects: 12
Study 10434232 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin phosphate sterile solution (IV infusion)
Number of subjects: 12
Study 7811160 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine mesylate
Number of subjects: 149
Study 7811160 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic medication dose reduction
Number of subjects: 149
Study 7811160 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 149
Study 7811160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 149
Study 7811160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 7811160 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 149
Study 2349364 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (12.5 mg) three times daily for 4 days
Number of subjects: 12
Study 2349364 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (10 mg) three times daily for 4 days
Number of subjects: 12
Study 2349364 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tianeptine and oxazepam
Number of subjects: 12
Study 37094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 12
Study 37094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31100713 — intervention group
Group type: COMPARATOR
Intervention: SBIRT
Number of subjects: 439
Study 31100713 — intervention group
Group type: COMPARATOR
Intervention: e‐SBIRT
Number of subjects: 439
Study 28244706 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based dietary and physical activity intervention (Her Shape Program)
Number of subjects: 31
Study 28244706 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 25870324 — intervention group
Group type: EXPERIMENTAL
Intervention: Typbar-TCV (single dose)
Number of subjects: 981
Study 25870324 — intervention group
Group type: COMPARATOR
Intervention: Typbar (Vi polysaccharide, single dose)
Number of subjects: 981
Study 25870324 — intervention group
Group type: EXPERIMENTAL
Intervention: Typbar-TCV (single dose) in OLT
Number of subjects: 981
Study 25870324 — intervention group
Group type: EXPERIMENTAL
Intervention: Typbar-TCV (2 years post-vaccination)
Number of subjects: 981
Study 25870324 — intervention group
Group type: EXPERIMENTAL
Intervention: Typbar-TCV (OLT)
Number of subjects: 981
Study 24059784 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment for Substance abuse and Partner violence (I-StoP)
Number of subjects: 52
Study 24059784 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral treatment addressing substance use disorders (CBT-SUD+)
Number of subjects: 52
Study 21865352 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous testosterone (TE, n = 8; 100 mg testosterone enanthate, im injection)
Number of subjects: 24
Study 21865352 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly cycled testosterone (MO, n = 8; alternating months of testosterone and placebo)
Number of subjects: 24
Study 21865352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL, n = 8)
Number of subjects: 24
Study 19273709 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly bolus irinotecan, FU, and leucovorin (IFL)
Number of subjects: 1264
Study 19273709 — intervention group
Group type: COMPARATOR
Intervention: Weekly bolus fluorouracil and leucovorin (FU/LV)
Number of subjects: 1264
Study 17390741 — intervention group
Group type: COMPARATOR
Intervention: Standard-exposure cyclosporine
Number of subjects: 89
Study 17390741 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-exposure cyclosporine
Number of subjects: 89
Study 17390741 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 15054036 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO + rHuG-CSF (arm A)
Number of subjects: 60
Study 15054036 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (arm B)
Number of subjects: 60
Study 15054036 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO alone after 12 weeks for responders in arm A
Number of subjects: 60
Study 15054036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per patient
Number of subjects: 60
Study 15054036 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment with FACT-An scale
Number of subjects: 60
Study 11964529 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotyping
Number of subjects: 541
Study 11964529 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping
Number of subjects: 541
Study 11964529 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 541
Study 9563888 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine administered after food
Number of subjects: 11
Study 9563888 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine administered after fasting
Number of subjects: 11
Study 7637045 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug solution (papaverine + phentolamine + prostaglandin E1)
Number of subjects: 20
Study 7637045 — intervention group
Group type: COMPARATOR
Intervention: 2-drug solution (papaverine + phentolamine)
Number of subjects: 20
Study 2515399 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen therapy
Number of subjects: 20
Study 2515399 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 20
Study 687502 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0
Study 687502 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 0
Study 687502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30726465 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of SPF 30 on the face, neck and chest (n=64)
Number of subjects: 95
Study 30726465 — intervention group
Group type: EXPERIMENTAL
Intervention: No sunscreens (n=10)
Number of subjects: 95
Study 30726465 — intervention group
Group type: COMPARATOR
Intervention: Confined from sun exposure for 24h (n=21)
Number of subjects: 95
Study 28319871 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG and IgM MDA-LDL
Number of subjects: 220
Study 28319871 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG and IgM apoB-IC
Number of subjects: 220
Study 28319871 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibody titers to MDA-LDL and apoB-IC
Number of subjects: 220
Study 26614140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Number of subjects: 240
Study 26614140 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing cuff before insertion
Number of subjects: 240
Study 26614140 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing mouth before removing laryngeal mask airway
Number of subjects: 240
Study 26614140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementary method)
Number of subjects: 240
Study 23223597 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg tribendimidine once
Number of subjects: 74
Study 23223597 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg tribendimidine daily for 3 days
Number of subjects: 74
Study 23223597 — intervention group
Group type: COMPARATOR
Intervention: 75 mg/kg praziquantel in 1 day divided in 3 doses
Number of subjects: 74
Study 23223597 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 74
Study 23223597 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose tribendimidine
Number of subjects: 74
Study 23223597 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 74
Study 21791091 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin 3,000 UaXa o.d.
Number of subjects: 274
Study 21791091 — intervention group
Group type: COMPARATOR
Intervention: UFH 5,000 IU t.i.d.
Number of subjects: 274
Study 21791091 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cancer
Number of subjects: 274
Study 21791091 — intervention group
Group type: COMPARATOR
Intervention: Patients without cancer
Number of subjects: 274
Study 19335078 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-enriched hydroxyapatite (mHA)
Number of subjects: 15
Study 19335078 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone (AB)
Number of subjects: 15
Study 16934269 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 56
Study 16934269 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 56
Study 15306157 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum clotted on room temperature (serum‐RT)
Number of subjects: 30
Study 15306157 — intervention group
Group type: COMPARATOR
Intervention: Serum clotted on ice (serum‐I)
Number of subjects: 30
Study 15306157 — intervention group
Group type: COMPARATOR
Intervention: Platelet poor plasma (PPP)
Number of subjects: 30
Study 15306157 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sCD40L in patients with thrombosis
Number of subjects: 30
Study 15306157 — intervention group
Group type: COMPARATOR
Intervention: Plasma sCD40L in patients without thrombosis
Number of subjects: 30
Study 11009268 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin plus anti-hypertensive drugs
Number of subjects: 60
Study 11009268 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive agents and diet control alone
Number of subjects: 60
Study 11009268 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive agents (normolipidemia)
Number of subjects: 60
Study 8827744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 428
Study 8827744 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 428
Study 1747505 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40mg h.s.
Number of subjects: 280
Study 1747505 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300mg h.s.
Number of subjects: 280
Study 1747505 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40mg h.s. and Ranitidine 300mg h.s.
Number of subjects: 280